Ann: Positive Interim Data from ATH434-202 Phase 2 Clinical Trial, page-128

Hi Skint,

Good find on a previous drug Dr Stamler had bought to market with impressive results.

$1B price is definately extremely impressive, and thats just for MSA not other potential diseases it may help treat.

Given that the drug has shown positive effects on late stage MSA patients, one could only expect better results, as the drug is removing the excess ferrous iron, therefore reducing oxidative stress on the cell, plus preventing iron aggregation, and restoring natural homeostasis.

Given the current SP following positive results, you wouldnt have expected to go back to lower levels pre release of results.

Positive read of the 201 study will definately move the market, but it will be interesting to see what is planned with the podcast tomorrow, and see what MST financials plans to assist move the company forward.